ReviewBMC cancer2018
Mechanisms of immune evasion in breast cancer.
Review in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04689945 (Metabolomic Profiling of Erector Spinae Plane Block for Breast Cancer Surgery), which is not on this map. Cited by 167 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Metabolomic Profiling of Erector Spinae Plane Block for Breast Cancer Surgery
Who cites it
167 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.Frontiers in immunology · 2021Pooled it
- Molecular Mechanisms Underlying Recurrence in Triple-Positive Breast Cancer (ER+/PR+/HER2+) and Potential Repurposing of Multi-Target Inhibitors.International journal of molecular sciences · 2026Review
- NSUN2/m5C/TPI1 axis promotes glycolysis and immune evasion in breast cancer.Journal of translational medicine · 2026Article
- Integrating network pharmacology with ex-vivo analysis to assess the effect of IL-2 in halting breast cancer: involvement of Treg/CTLA-4/Blimp-1/caspase-3.Scientific reports · 2026Article
- Integrated spatial transcriptomics and pan-cancer XGBoost modeling uncover spatial drivers of immune exclusion and predict immunotherapy response.Cancer immunology, immunotherapy : CII · 2026Article
- Bridging biomaterials and immunotherapy: hydrogel strategies for next-generation CAR-T cell treatment.Stem cell research & therapy · 2026Review
- Impact of oncogenic viruses on autoimmune diseases and tumorigenesis.Infectious agents and cancer · 2026Review
- Comparative effects of a TLR7/8 agonist and doxorubicin on immune checkpoint modulation and apoptosis in 4T1 breast cancer cells.Biochemistry and biophysics reports · 2026Article
- Review
- Role of SERPINA1 in the tumor immune microenvironment of breast cancer and construction of a prognostic model.Discover oncology · 2026Article
- Galectin-9-driven immunosuppressive macrophage population shapes the lymph node metastatic microenvironment.British journal of cancer · 2026Article
- Minimal Residual Disease Detection: Bridging Molecular and Clinical Strategies for Recurrence Prevention in Gynecologic Cancers.International journal of molecular sciences · 2025Review
- Mechanism and role of regulated cell death in tumor immunity and immunotherapy.Cancer communications (London, England) · 2025Review
- Integrated multi-omics analysis identifies SELENOP and PKMYT1 as immune-metabolic hub genes in breast cancer.Biochemistry and biophysics reports · 2025Article
- Cruciferous Vegetables, Bioactive Metabolites, and Microbiome for Breast Cancer Prevention.Annual review of nutrition · 2025Review
- [The TGF‑β/miR-23a-3p/IRF1 axis mediates immune escape of hepatocellular carcinoma by inhibiting major histocompatibility complex class I].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Polyamine metabolism and immune related genes as prognostic features in breast cancer: a novel risk model approach.Translational cancer research · 2025Article
- The role of cytokines in pediatric hematologic malignancies: mechanisms of tumor progression and therapeutic implications - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- PCYT2 mediates ovarian epithelial cancer metastasis by regulating cell membrane fluidity through the AMPK/FOXO1 signalling pathway.Scientific reports · 2025Article
107 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Tumors develop multiple mechanisms of immune evasion as they progress, with some cancer types being inherently better at 'hiding' than others. With an increased understanding of tumor immune surveillance, immunotherapy has emerged as a promising treatment strategy for breast cancer, despite historically being thought of as an immunologically silent neoplasm. Some types of cancer, such as melanoma, bladder, and renal cell carcinoma, have demonstrated a durable response to immunotherapeutic intervention, however, breast neoplasms have not shown the same efficacy. The causes of breast cancer's immune silence derive from mechanisms that diminish immune recognition and others that promote strong immunosuppression. It is the mechanisms of immune evasion in breast cancers that are poorly defined. Thus, further characterization is critical for the development of better therapies. This brief review will seek to provide insight into the possible causes of weak immunogenicity and immune suppression mediated by breast cancers and highlight current immunotherapies being used to restore immune responses to breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.